Clinical Trials Logo

Leukemia, Prolymphocytic, B-Cell clinical trials

View clinical trials related to Leukemia, Prolymphocytic, B-Cell.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04312841 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Start date: September 15, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well letermovir works for the prevention of cytomegalovirus reactivation in patients with hematological malignancies treated with alemtuzumab. Patients receiving treatment with alemtuzumab may experience cytomegalovirus reactivation. Letermovir may block cytomegalovirus replication and prevent infection.

NCT ID: NCT03479268 Active, not recruiting - Clinical trials for Recurrent Mantle Cell Lymphoma

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

Start date: March 22, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of pevonedistat when given together with ibrutinib in participants with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has come back or has stopped responding to other treatments. Pevonedistat and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02153580 Active, not recruiting - Clinical trials for Recurrent Mantle Cell Lymphoma

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

Start date: September 24, 2014
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of cellular immunotherapy following chemotherapy in treating patients with non-Hodgkin lymphomas, chronic lymphocytic leukemia, or B-cell prolymphocytic leukemia that has come back. Placing a modified gene into white blood cells may help the body build an immune response to kill cancer cells.

NCT ID: NCT01589302 Active, not recruiting - Clinical trials for Recurrent Small Lymphocytic Lymphoma

PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

Start date: May 21, 2012
Phase: Phase 2
Study type: Interventional

This is a Phase II, single institution open-label, non-randomized monotherapy study to evaluate the clinical efficacy and durable disease control of PCI-32765 administered to patients with relapsed/refractory CLL/SLL/PLL of all risk categories with patients having deletion 17p13 independently evaluated.